Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1

  1. Edward Kim
  2. Yuan Wang
  3. Sun-Jung Kim
  4. Miriam Bornhorst
  5. Emmanuelle S Jecrois
  6. Todd E Anthony
  7. Chenran Wang
  8. Yi E Li
  9. Jun-Lin Guan
  10. Geoffrey G Murphy
  11. Yuan Zhu  Is a corresponding author
  1. University of Michigan Medical School, United States
  2. Children's National Medical Center, United States
  3. Rockefeller University, United States
  4. University of Cincinnati College of Medicine, United States

Abstract

Individuals with neurofibromatosis type 1 (NF1) frequently exhibit cognitive and motor impairments and characteristics of autism. The cerebellum plays a critical role in motor control, cognition, and social interaction, suggesting that cerebellar defects likely contribute to NF1-associated neurodevelopmental disorders. Here we show that Nf1 inactivation during early, but not late stages of cerebellar development, disrupts neuronal lamination, which is partially caused by overproduction of glia and subsequent disruption of the Bergmann glia (BG) scaffold. Specific Nf1 inactivation in glutamatergic neuronal precursors causes premature differentiation of granule cell (GC) precursors and ectopic production of unipolar brush cells (UBCs), indirectly disrupting neuronal migration. Transient MEK inhibition during a neonatal window prevents cerebellar developmental defects and improves long-term motor performance of Nf1-deficient mice. This study reveals essential roles of Nf1 in GC/UBC migration by generating correct numbers of glia and controlling GC/UBC fate-specification/differentiation, identifying a therapeutic prevention strategy for multiple NF1-associcated developmental abnormalities.

Article and author information

Author details

  1. Edward Kim

    Division of Molecular Medicine and Genetics, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, United States
    Competing interests
    The authors declare that no competing interests exist.
  2. Yuan Wang

    Gilbert Family Neurofibromatosis Institute, Center for Cancer and Immunology Research, Children's National Medical Center, Washington, United States
    Competing interests
    The authors declare that no competing interests exist.
  3. Sun-Jung Kim

    Gilbert Family Neurofibromatosis Institute, Center for Cancer and Immunology Research, Children's National Medical Center, Washington, United States
    Competing interests
    The authors declare that no competing interests exist.
  4. Miriam Bornhorst

    Gilbert Family Neurofibromatosis Institute, Center for Cancer and Immunology Research, Children's National Medical Center, Washington, United States
    Competing interests
    The authors declare that no competing interests exist.
  5. Emmanuelle S Jecrois

    Gilbert Family Neurofibromatosis Institute, Center for Cancer and Immunology Research, Children's National Medical Center, Washington, United States
    Competing interests
    The authors declare that no competing interests exist.
  6. Todd E Anthony

    Laboratory of Molecular Biology, Rockefeller University, New York, United States
    Competing interests
    The authors declare that no competing interests exist.
  7. Chenran Wang

    Department of Cancer Biology, University of Cincinnati College of Medicine, Cincinnati, United States
    Competing interests
    The authors declare that no competing interests exist.
  8. Yi E Li

    Division of Molecular Medicine and Genetics, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, United States
    Competing interests
    The authors declare that no competing interests exist.
  9. Jun-Lin Guan

    Division of Molecular Medicine and Genetics, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, United States
    Competing interests
    The authors declare that no competing interests exist.
  10. Geoffrey G Murphy

    Molecular and Behavioral Neuroscience Institute, University of Michigan Medical School, Ann Arbor, United States
    Competing interests
    The authors declare that no competing interests exist.
  11. Yuan Zhu

    Gilbert Family Neurofibromatosis Institute, Center for Cancer and Immunology Research, Children's National Medical Center, Washington, United States
    For correspondence
    yzhu@childrensnational.org
    Competing interests
    The authors declare that no competing interests exist.

Reviewing Editor

  1. Duojia Pan, Howard Hughes Medical Institute, Johns Hopkins University School of Medicine, United States

Ethics

Animal experimentation: All mice in this study were cared for according to the guidelines that were approved by the Animal Care and Use Committees of the University of Michigan at Ann Arbor, MI and the Children's National Medical Center in Washington, DC. The approved protocol number at the University of Michigan is PRO00004481. The project (ID# 30001543) was approved by the IACUC (Protocol#: 309-13-09) of the Children's National Medical Center at Washington.

Version history

  1. Received: October 13, 2014
  2. Accepted: December 22, 2014
  3. Accepted Manuscript published: December 23, 2014 (version 1)
  4. Version of Record published: January 21, 2015 (version 2)

Copyright

© 2014, Kim et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 2,294
    views
  • 414
    downloads
  • 21
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Edward Kim
  2. Yuan Wang
  3. Sun-Jung Kim
  4. Miriam Bornhorst
  5. Emmanuelle S Jecrois
  6. Todd E Anthony
  7. Chenran Wang
  8. Yi E Li
  9. Jun-Lin Guan
  10. Geoffrey G Murphy
  11. Yuan Zhu
(2014)
Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1
eLife 3:e05151.
https://doi.org/10.7554/eLife.05151

Share this article

https://doi.org/10.7554/eLife.05151

Further reading

    1. Developmental Biology
    Zhimin Xu, Zhao Wang ... Yingchuan B Qi
    Research Article

    Precise developmental timing control is essential for organism formation and function, but its mechanisms are unclear. In C. elegans, the microRNA lin-4 critically regulates developmental timing by post-transcriptionally downregulating the larval-stage-fate controller LIN-14. However, the mechanisms triggering the activation of lin-4 expression toward the end of the first larval stage remain unknown. We demonstrate that the transmembrane transcription factor MYRF-1 is necessary for lin-4 activation. MYRF-1 is initially localized on the cell membrane, and its increased cleavage and nuclear accumulation coincide with lin-4 expression timing. MYRF-1 regulates lin-4 expression cell-autonomously and hyperactive MYRF-1 can prematurely drive lin-4 expression in embryos and young first-stage larvae. The tandem lin-4 promoter DNA recruits MYRF-1GFP to form visible loci in the nucleus, suggesting that MYRF-1 directly binds to the lin-4 promoter. Our findings identify a crucial link in understanding developmental timing regulation and establish MYRF-1 as a key regulator of lin-4 expression.

    1. Developmental Biology
    2. Structural Biology and Molecular Biophysics
    Samuel C Griffiths, Jia Tan ... Hsin-Yi Henry Ho
    Research Article Updated

    The receptor tyrosine kinase ROR2 mediates noncanonical WNT5A signaling to orchestrate tissue morphogenetic processes, and dysfunction of the pathway causes Robinow syndrome, brachydactyly B, and metastatic diseases. The domain(s) and mechanisms required for ROR2 function, however, remain unclear. We solved the crystal structure of the extracellular cysteine-rich (CRD) and Kringle (Kr) domains of ROR2 and found that, unlike other CRDs, the ROR2 CRD lacks the signature hydrophobic pocket that binds lipids/lipid-modified proteins, such as WNTs, suggesting a novel mechanism of ligand reception. Functionally, we showed that the ROR2 CRD, but not other domains, is required and minimally sufficient to promote WNT5A signaling, and Robinow mutations in the CRD and the adjacent Kr impair ROR2 secretion and function. Moreover, using function-activating and -perturbing antibodies against the Frizzled (FZ) family of WNT receptors, we demonstrate the involvement of FZ in WNT5A-ROR signaling. Thus, ROR2 acts via its CRD to potentiate the function of a receptor super-complex that includes FZ to transduce WNT5A signals.